Antiviral CD8⁺ T Cells Restricted by Human Leukocyte Antigen Class II Exist during Natural HIV Infection and Exhibit Clonal Expansion
Name
1-s2.0-S1074761316303843-main.pdf
Size
2.75 MB
Format
Adobe PDF
Checksum (MD5)
26dd246cc58a0469867dc26c234e6dcf
Author(s) • • • • • • • • •
Ranasinghe, Srinika
Lamothe, Pedro A.
Soghoian, Damien Z.
Cole, Michael B.
Yosef, Nir
Jones, R. Brad
Donaghey, Faith
Nwonu, Chioma
Jani, Priya
Clayton, Gina M.
Date Issued
October 2016
Journal
Immunity
Publisher
Elsevier
Citation
Ranasinghe, Srinika et al. “Antiviral CD8⁺ T Cells Restricted by Human Leukocyte Antigen Class II Exist During Natural HIV Infection and Exhibit Clonal Expansion.” Immunity 45, 4 (October 2016): 917–930 © 2016 The Author(s)
Version
Final published version
Abstract
CD8⁺ T cell recognition of virus-infected cells is characteristically restricted by major histocompatibility complex (MHC) class I, although rare examples of MHC class II restriction have been reported in Cd4-deficient mice and a macaque SIV vaccine trial using a recombinant cytomegalovirus vector. Here, we demonstrate the presence of human leukocyte antigen (HLA) class II-restricted CD8⁺ T cell responses with antiviral properties in a small subset of HIV-infected individuals. In these individuals, T cell receptor β (TCRβ) analysis revealed that class II-restricted CD8⁺ T cells underwent clonal expansion and mediated killing of HIV-infected cells. In one case, these cells comprised 12% of circulating CD8⁺ T cells, and TCRα analysis revealed two distinct co-expressed TCRα chains, with only one contributing to binding of the class II HLA-peptide complex. These data indicate that class II-restricted CD8⁺ T cell responses can exist in a chronic human viral infection, and may contribute to immune control. Keywords: HIV; TCR; CD8⁺ T cells; vaccines; HLA;MHC class II
MIT Department
Institute for Medical Engineering and Science
Terms of Use
Creative Commons Attribution 4.0 International License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/J.IMMUNI.2016.09.015